Skip to main content

Table 2 Inflammatory cell classification of nasal polyps, spirometry and medication of patients with CRSwNP for modelling

From: Risk factors associated with comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: a cross-sectional study

Parameter

Whole group (n = 150)

CRSwNP with asthma (n = 80)

CRSwNP without asthma (n = 70)

P value

Inflammatory cell type in nasal polyps

Lymphocyte, cells/HP

76.9 (40.0, 150.0)

71.0 (39.3, 122.0)

82.7 (44.0, 180.0)

0.232

Lymphocyte, %

39.3 ± 22.6

37.1 ± 21.2

42.9 ± 24.6

0.163

Plasma cel, cells/HP

30.0 (16.4, 52.8)

30.0 (18.7, 58.7)

30.0 (10.0, 40.0)

0.279

Plasma cell, %

12.5 (6.6, 20.9)

14.4 (6.8, 24.7)

10.3 (5.3, 18.2)

0.162

Eosinophil, cells/HP

80.0 (27.0, 200.0)

80.0 (30.0, 201.8)

70.0 (15.3, 180.0)

0.563

Eosinophil, %

37.3 (12.9, 65.1)

38.8 (16.7, 66.7)

30.9 (9.7, 54.5)

0.160

Neutrophil, cells/HP

0.7 (0.0, 10.0)

0.3 (0.0, 10.0)

3.7 (0.0, 20.0)

0.183

Neutrophil, %

0.3 (0.0, 3.9)

0.3 (0.0, 3.6)

1.3 (0.0, 7.1)

0.219

Eosinophil ≥ 10%, n (%)

101 (80.2)

67 (84.8)

34 (72.3)

0.090

Eosinophil > 27%, n (%)

80 (63.5)

54 (68.4)

26 (55.3)

0.142

Spirometry

FEV1/FVC, %

83.4 (80.4, 89.0)

81.3 (68.3, 85.9)

82.9 (82.8, 90.9)

 < 0.001*

FEV1%predicted, %

93.1 ± 17.8

87.2 ± 19.4

99.9 ± 12.8

 < 0.001*

Medication before enrolment

Not taking drugs, n (%)

22 (14.7)

1 (1.3)

21 (30.0)

 < 0.001*

Topical corticosteroids, n (%)

120 (80.0)

79(98.8)

41 (58.6)

 < 0.001*

Leukotriene receptor antagonist, n (%)

72 (48.0)

45 (56.3)

27 (38.6)

0.031*

Antihistamines, n (%)

60 (40.0)

28 (35.0)

32(45.7)

0.181

  1. Data are presented as No. (%) for qualitative variables, as mean ± standard deviation for normal distribution quantitative parameters, as median (25th, 75th percentiles) for abnormal distribution quantitative parameters
  2. CRSwNP Chronic rhinosinusitis with nasal polyps; HP High power; FEV1 Forced expiratory volume in 1 s; FVC Forced vital capacity
  3. Totally nasal polyp tissues from 126 patients with CRSwNP were analyzed, including 79 patients with asthma and 47 patients without
  4. * statistical significance between CRSwNP with asthma and CRSwNP without asthma